The role of EGFR-TK inhibition in non-small cell lung cancer

被引：1

作者：

Giaccone, G ^{[1
]}

机构：

[1] Vrije Univ Amsterdam, Med Ctr, Div Med Oncol, Amsterdam, Netherlands

来源：

ONKOLOGIE | 2005年 / 28卷 / 12期

关键词：

D O I：

10.1159/000089415

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

引用

页码：619 / 620

页数：2

共 9 条

[1] Gefitinib is active in patients with brain metastases from non-small cell lung cancer and response is related to skin toxicity [J].

Chiu, CH ;

Tsai, CM ;

Chen, YM ;

Chiang, SC ;

Liou, JL ;

Perng, RP .

LUNG CANCER, 2005, 47 (01) :129-138

[2] Mutations in the epidermal growth factor receptor and in KRAS are predictive and prognostic indicators in patients with non-small-cell lung cancer treated with chemotherapy alone and in combination with erlotinib [J].

Eberhard, DA ;

Johnson, BE ;

Amler, LC ;

Goddard, AD ;

Heldens, SL ;

Herbst, RS ;

Ince, WL ;

Jänne, PA ;

Januario, T ;

Johnson, DH ;

Klein, P ;

Miller, VA ;

Ostland, MA ;

Ramies, DA ;

Sebisanovic, D ;

Stinson, JA ;

Zhang, YR ;

Seshagiri, S ;

Hillan, KJ .

JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (25) :5900-5909

[3] Multi-institutional randomized phase II trial of gefitinib for previously treated patients with advanced non-small-cell lung cancer [J].

Fukuoka, M ;

Yano, S ;

Giaccone, G ;

Tamura, T ;

Nakagawa, K ;

Douillard, JY ;

Nishiwaki, Y ;

Vansteenkiste, J ;

Kudoh, S ;

Rischin, D ;

Eek, R ;

Horai, T ;

Noda, K ;

Takata, I ;

Smit, E ;

Averbuch, S ;

Macleod, A ;

Feyereislova, A ;

Dong, RP ;

Baselga, J .

JOURNAL OF CLINICAL ONCOLOGY, 2003, 21 (12) :2237-2246

[4] Epidermal growth factor receptor inhibitors in the treatment of non-small-cell lung cancer [J].

Giaccone, G .

JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (14) :3235-3242

[5] Efficacy of gefitinib, an inhibitor of the epidermal growth factor receptor tyrosine kinase, in symptomatic patients with non-small cell lung cancer - A randomized trial [J].

Kris, MG ;

Natale, RB ;

Herbst, RS ;

Lynch, TJ ;

Prager, D ;

Belani, CP ;

Schiller, JH ;

Kelly, K ;

Spiridonidis, H ;

Sandler, A ;

Albain, KS ;

Cella, D ;

Wolf, MK ;

Averbuch, SD ;

Ochs, JJ ;

Kay, AC .

JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2003, 290 (16) :2149-2158

[6] EGFR mutations in non-small-cell lung cancer:: Analysis of a large series of cases and development of a rapid and sensitive method for diagnostic screening with potential implications on pharmacologic treatment [J].

Marchetti, A ;

Martella, C ;

Felicioni, L ;

Barassi, F ;

Salvatore, S ;

Chella, A ;

Camplese, PP ;

Iarussi, T ;

Mucilli, F ;

Mezzetti, A ;

Cuccurullo, F ;

Sacco, R ;

Buttitta, F .

JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (04) :857-865

[7] Epidermal growth factor receptor mutations, small-molecule kinase inhibitors, and non-small-cell lung cancer: Current knowledge and future directions [J].

Pao, W ;

Miller, VA .

JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (11) :2556-2568

[8] EGFR tyrosine kinase inhibitors in non-small cell lung cancer: Report of a 3-year compassionate use experience with gefitinib in stage IIIB/IV outpatients [J].

Reck, M ;

Gatzemeier, U .

ONKOLOGIE, 2005, 28 (12) :623-627

[9] Erlotinib in lung cancer - Molecular and clinical predictors of outcome [J].

Tsao, MS ;

Sakurada, A ;

Cutz, JC ;

Zhu, CQ ;

Kamel-Reid, S ;

Squire, J ;

Lorimer, I ;

Zhang, T ;

Liu, N ;

Daneshmand, M ;

Marrano, P ;

Santos, GD ;

Lagarde, A ;

Richardson, F ;

Seymour, L ;

Whitehead, M ;

Ding, KY ;

Pater, J ;

Shepherd, FA .

NEW ENGLAND JOURNAL OF MEDICINE, 2005, 353 (02) :133-144

← 1 →